Mortality and Antidepressants Among Individuals With Autism Spectrum Disorder: A Population-Based Cohort Study / Vincent Chin-Hung CHEN in Autism Research, 19-9 (September 2026)  

Public ISBD [article]  inAutism Research > 19-9 (September 2026) . - p. e70302 Titre : Mortality and Antidepressants Among Individuals With Autism Spectrum Disorder: A Population-Based Cohort Study Type de document : texte imprimé Auteurs : Vincent Chin-Hung CHEN, Auteur ; Yu-Hsin HUANG, Auteur ; Yi-Lung CHEN, Auteur ; Michael E. DEWEY, Auteur ; Tai-Hsin HUNG, Auteur ; Shu- I. WU, Auteur Article en page(s) : p. e70302 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : ABSTRACT Individuals with autism spectrum disorder (ASD) often experience premature mortality and co-occurring psychiatric conditions, for which antidepressants are commonly prescribed. However, the long-term safety of antidepressant use in this population remains unclear. Using data from the Taiwan National Health Insurance Research Database, we emulated a target trial to examine the association between antidepressant use and mortality among individuals with ASD aged 6?64?years diagnosed between 2000 and 2016. A three-step approach of cloning, censoring, and inverse probability of censoring weighting was applied to address immortal-time bias. Participants were followed for up to 5?years to assess all-cause, suicide, and accidental-cause mortality. Among 33,939 eligible individuals, 779 initiated antidepressants within a 3-month grace period. Antidepressant use was not associated with all-cause or suicide mortality overall. However, it was significantly associated with reduced accidental-cause mortality at both 2 (HR?=?0.15; 95% CI, 0.04?0.53) and 5?years (HR?=?0.05; 95% CI, 0.01?0.20). Subgroup analysis revealed increased 2-year all-cause mortality among youths (HR?=?4.40; 95% CI, 1.10?17.58) but significantly decreased 5-year accidental mortality in the age groups of 6?15?years (HR?=?0.06; 95% CI, 0.01?0.41) and over 24?years (HR?=?0.06; 95% CI, 0.01?0.42). Additionally, decreased 5-year suicide mortality was observed in the 16?24 age group (HR?=?0.17; 95% CI, 0.05?0.61). While antidepressant use may reduce accidental mortality in individuals with ASD, age-specific risks warrant careful consideration and monitoring, particularly among younger populations. En ligne : https://doi.org/10.1002/aur.70302 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=592 [article] Mortality and Antidepressants Among Individuals With Autism Spectrum Disorder: A Population-Based Cohort Study [texte imprimé] / Vincent Chin-Hung CHEN, Auteur ; Yu-Hsin HUANG, Auteur ; Yi-Lung CHEN, Auteur ; Michael E. DEWEY, Auteur ; Tai-Hsin HUNG, Auteur ; Shu- I. WU, Auteur . - p. e70302. Langues : Anglais (eng) in Autism Research > 19-9 (September 2026) . - p. e70302 Index. décimale : PER Périodiques Résumé : ABSTRACT Individuals with autism spectrum disorder (ASD) often experience premature mortality and co-occurring psychiatric conditions, for which antidepressants are commonly prescribed. However, the long-term safety of antidepressant use in this population remains unclear. Using data from the Taiwan National Health Insurance Research Database, we emulated a target trial to examine the association between antidepressant use and mortality among individuals with ASD aged 6?64?years diagnosed between 2000 and 2016. A three-step approach of cloning, censoring, and inverse probability of censoring weighting was applied to address immortal-time bias. Participants were followed for up to 5?years to assess all-cause, suicide, and accidental-cause mortality. Among 33,939 eligible individuals, 779 initiated antidepressants within a 3-month grace period. Antidepressant use was not associated with all-cause or suicide mortality overall. However, it was significantly associated with reduced accidental-cause mortality at both 2 (HR?=?0.15; 95% CI, 0.04?0.53) and 5?years (HR?=?0.05; 95% CI, 0.01?0.20). Subgroup analysis revealed increased 2-year all-cause mortality among youths (HR?=?4.40; 95% CI, 1.10?17.58) but significantly decreased 5-year accidental mortality in the age groups of 6?15?years (HR?=?0.06; 95% CI, 0.01?0.41) and over 24?years (HR?=?0.06; 95% CI, 0.01?0.42). Additionally, decreased 5-year suicide mortality was observed in the 16?24 age group (HR?=?0.17; 95% CI, 0.05?0.61). While antidepressant use may reduce accidental mortality in individuals with ASD, age-specific risks warrant careful consideration and monitoring, particularly among younger populations. En ligne : https://doi.org/10.1002/aur.70302 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=592

Probiotic intervention in young children with autism spectrum disorder in Taiwan: A randomized, double-blinded, placebo-controlled trial / Jia-En WANG ; Fang-Ju SUN ; Yu-Hsin HUANG ; Hui-Ju CHEN in Research in Autism Spectrum Disorders, 109 (November 2023)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 109 (November 2023) . - 102256 Titre : Probiotic intervention in young children with autism spectrum disorder in Taiwan: A randomized, double-blinded, placebo-controlled trial Type de document : texte imprimé Auteurs : Jia-En WANG, Auteur ; Fang-Ju SUN, Auteur ; Yu-Hsin HUANG, Auteur ; Hui-Ju CHEN, Auteur Article en page(s) : 102256 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder (ASD)  Preschool  Probiotic  Psychobiotic  Anxious/depressed Index. décimale : PER Périodiques Résumé : Background The impact of psychobiotics on ASD is unclear. Method In this double-blinded, randomized, placebo-controlled trial, 86 children (aged 2.5-7 years) with ASD were recruited and assigned randomly to either the probiotic or placebo group to explore the effects of the probiotic Lactobacillus plantarum PS128 (PS128). During the first 2 months of the study, the children received either the probiotic or placebo. After that, all of the children received PS128 for 2 more months. We categorized individuals who took PS128 for the entire 4-month duration as the "PS128 early use group" (E group), while those who initially received the placebo for 2 months and then took PS128 for the subsequent 2 months were classified as the "PS128 late use group" (L group). Results After adjusting for possible confounders, the results showed that the anxious/depressed subscale score of the Achenbach System of Empirically Based Assessment significantly improved in the E group after the first 2-month intervention (P = 0.044) when compared to the L group. In the subsequent 2 months, the L group showed a significant improvement in this subscale (P = 0.017). While the improvement observed during the first two months was not sustained on average in the E group from V2 to V3, this variability can be attributed to the influence of an outlier. Upon analyzing the hyperactivity subscale of the Attention-Deficit/Hyperactivity Disorder Test, no significant differences were found across multiple time points. Conclusions The results support that PS128 has beneficial effects on behavioral and emotional problems in young children with ASD. En ligne : https://doi.org/10.1016/j.rasd.2023.102256 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=517 [article] Probiotic intervention in young children with autism spectrum disorder in Taiwan: A randomized, double-blinded, placebo-controlled trial [texte imprimé] / Jia-En WANG, Auteur ; Fang-Ju SUN, Auteur ; Yu-Hsin HUANG, Auteur ; Hui-Ju CHEN, Auteur . - 102256. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 109 (November 2023) . - 102256 Mots-clés : Autism spectrum disorder (ASD)  Preschool  Probiotic  Psychobiotic  Anxious/depressed Index. décimale : PER Périodiques Résumé : Background The impact of psychobiotics on ASD is unclear. Method In this double-blinded, randomized, placebo-controlled trial, 86 children (aged 2.5-7 years) with ASD were recruited and assigned randomly to either the probiotic or placebo group to explore the effects of the probiotic Lactobacillus plantarum PS128 (PS128). During the first 2 months of the study, the children received either the probiotic or placebo. After that, all of the children received PS128 for 2 more months. We categorized individuals who took PS128 for the entire 4-month duration as the "PS128 early use group" (E group), while those who initially received the placebo for 2 months and then took PS128 for the subsequent 2 months were classified as the "PS128 late use group" (L group). Results After adjusting for possible confounders, the results showed that the anxious/depressed subscale score of the Achenbach System of Empirically Based Assessment significantly improved in the E group after the first 2-month intervention (P = 0.044) when compared to the L group. In the subsequent 2 months, the L group showed a significant improvement in this subscale (P = 0.017). While the improvement observed during the first two months was not sustained on average in the E group from V2 to V3, this variability can be attributed to the influence of an outlier. Upon analyzing the hyperactivity subscale of the Attention-Deficit/Hyperactivity Disorder Test, no significant differences were found across multiple time points. Conclusions The results support that PS128 has beneficial effects on behavioral and emotional problems in young children with ASD. En ligne : https://doi.org/10.1016/j.rasd.2023.102256 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=517

---

1 (1 - 2 / 2) Par page : 25 50 100 200